ModifiedUnitedHealthcarePolicy CSO36TNX

Electrical Stimulation for the Treatment of Pain and Muscle Rehabilitation (for Tennessee Only)

Medical policy governing coverage of electrical stimulation modalities for Medicaid and CoverKids members in Tennessee, including TENS, NMES, and various percutaneous and implanted neuromodulation therapies.

Policy Summary

PayerUnitedHealthcare

PolicyElectrical Stimulation for the Treatment of Pain and Muscle Rehabilitation (for Tennessee Only)

Policy CodePolicy CSO36TNX

Change TypeReference & supporting information updates

Effective DateMar 1, 2025

Next Review Date

Key ActionVerify prior authorization and document prior conservative therapies (e.g., >90 days medical management and at least one course of physical therapy) before considering implantable restorative neurostimulation.

SourceLink

POLICY UPDATE CHANGES

Coverage Rationale Updated reference link to the TennCare Medicaid, Chapter 1200-13-13-.10: Exclusions

Supporting Information Updated Description of Services, Clinical Evidence, FDA, and References sections to reflect the most current information

Archived previous policy version CSO36TN.W

Tennessee-onlyjurisdiction

03/01/2025policy revision date

E0770FES HCPCS example

mixed/limitedevidence strength

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

multipledevice & modality types

Coverage Criteria for Electrical Stimulation Therapies

inv-01: NMES — Medically Necessary Indications

Covered when ANY of the following are met:

NMES covered indications: Disuse muscle atrophy not of neurological origin (e.g., casting, splinting, contractures).

From policy Coverage Rationale

NMES covered indications: Used as part of a comprehensive lower limb rehabilitation program following total knee arthroplasty (initiated early post-op as described in trials).

From policy Coverage Rationale and TKA trial descriptions

NMES covered indications: To improve upper extremity function in persons with partial paralysis following stroke when used as part of a comprehensive rehabilitation program.

From policy Coverage Rationale and stroke rehabilitation evidence

inv-02: Unproven / Not Medically Necessary Modalities

The following modalities are considered unproven and not medically necessary due to insufficient evidence of efficacy:

Unproven modalities: Microcurrent electrical nerve stimulation (MENS).

Listed as unproven in policy

Unproven modalities: Interferential therapy (IFT) for musculoskeletal disorders or to facilitate healing of nonsurgical soft tissue injuries or bone fractures.

Listed as unproven in policy

Unproven modalities: Percutaneous electrical nerve stimulation (PENS)/percutaneous neuromodulation therapy (PNT).

Listed as unproven in policy

Unproven modalities: Percutaneous electrical nerve field stimulation (PENFS).

inv-03: NMES — supported rehabilitative uses

Evidence-supported rehabilitative contexts (descriptive — no additional formal coverage logic provided here):

NMES-supported indications: Treatment of disuse atrophy when nerve supply to the muscle is intact; NMES used as rehabilitative regimen to prevent or reverse atrophy.

Supported by systematic reviews/trials noted in policy

NMES-supported indications: Adjunct to standard rehabilitation after total knee arthroplasty (early post-op NMES regimens showed improved quadriceps strength and early functional outcomes in RCTs).

TKA RCT evidence (Stevens-Lapsley et al., 2012) described in policy

NMES-supported indications: Adjunctive use in ACL reconstruction rehabilitation and other perioperative quadriceps strengthening protocols to attenuate weakness during early recovery.

Small RCTs cited in policy (ACL reconstruction) support early improvements

inv-04: Restorative neurostimulation

Implantable restorative neurostimulation (descriptive — device-specific justification required; trials enrolled refractory patients):

Restorative neurostimulation: Minimally invasive implanted system targeting multifidus muscle (example: ReActiv8) intended as rehabilitative therapy for impaired neuromuscular control in chronic mechanical low back pain.

Device indication and description from policy; evidence requires device-specific documentation

Restorative neurostimulation — trial context: Trials enrolled patients refractory to conservative care (see conservative-treatment criteria); evidence includes RCT and single-arm studies with limitations and requires careful justification for implantation.

From policy discussion of ReActiv8 evidence and HTA findings

inv-05: Cerebral Palsy — supportive evidence

Supportive pediatric cerebral palsy evidence (descriptive):

CP NMES evidence: NMES programs in children with cerebral palsy demonstrated improvements in muscle strength, biomechanics of movement, and functional mobility in systematic review(s) and RCTs; programs varied from 4–48 weeks and were often home-based or professional-delivered.

Cobo-Vicente et al. systematic review and Pool et al. RCTs summarized in policy

inv-06: Stroke — motor and dysphagia

Post-stroke motor and dysphagia applications (evidence varies by timing, severity, and protocol):

Gait and motor recovery post-stroke: NMES (including CCFES variants) has shown improvements in dorsiflexion strength, walking speed, ADLs and some motor measures in RCTs and systematic reviews; benefits often depend on timing (subacute) and severity of paresis.

Multiple trials and meta-analyses cited in policy

Dysphagia: NMES combined with swallowing therapy improved swallowing function and related outcomes in multiple RCTs/meta-analyses; subgroup analyses suggest greater effects when onset <20 days and treatment courses ≤4 weeks, but heterogeneity and bias limit certainty.onset < 20 days and treatment <= 4 weeks

Wang et al. meta-analysis and other reviews summarized in policy

inv-07: COPD and pulmonary rehabilitation

Respiratory/pulmonary NMES evidence and implications:

COPD inpatient/ventilated: In COPD patients on mechanical ventilation, small RCTs/meta-analyses report NMES may improve functional independence and shorten ventilation time, but evidence is limited and heterogeneous.

Gutierrez-Arias et al. review of 4 RCTs summarized in policy

COPD outpatient/rehab: NMES can increase quadriceps force and submaximal exercise endurance in COPD outpatients in some trials, but evidence quality is low and NMES should not replace conventional pulmonary rehabilitation.

Wu et al. and Cochrane findings summarized in policy

inv-08: Hospital-acquired disability

Hospitalized patients / prevention of hospital-acquired disability — summarized trial evidence:

Hospital-acquired disability: Systematic reviews and RCTs report small-to-moderate effects of NMES on muscle strength, walking performance and muscle size in hospitalized/ICU populations, though heterogeneity and risk of bias limit certainty.

Alqurashi et al. systematic review and Takino RCT cited in policy

inv-09: Evidence summaries by modality and condition

Condensed evidence summaries by modality and condition (informational — used to inform coverage stance):

NMES - hospitalized/ICU/postoperative: Systematic reviews and RCTs indicate NMES may modestly improve muscle strength, size and some functional outcomes in hospitalized, ICU and early post-op settings; protocol heterogeneity and variable study quality temper conclusions.

Alqurashi et al., Takino, and other trials summarized in policy

IFC/IFT - musculoskeletal: Interferential current/IFT shows inconsistent evidence: some meta-analyses report short-term pain relief versus placebo but no consistent additional benefit when added to standard care; NICE recommends against routine offering for some indications (e.g., knee OA, chronic primary pain, LBP).short-term benefit primarily

Hussein et al., Chen et al., and NICE guidance cited

PENS/TEAS/TEAS in perioperative settings reduced short-term pain and opioid consumption in multiple RCTs/meta-analyses; heterogeneity limits broad recommendations and prior authorization/documentation of indication and protocol is advised.

inv-10: Modality-specific coverage considerations

Modality-specific coverage considerations drawn from evidence and guideline summaries:

IFC/IFT for musculoskeletal pain: Evidence is heterogeneous and of low–moderate quality; short-term pain relief vs placebo is reported but NICE guidance recommends against routine use for some indications (knee OA, chronic primary pain, LBP).

NICE and systematic reviews summarized in policy

MENS / microcurrent therapy: Small RCTs/meta-analyses show modest short-term pain reductions in some conditions (e.g., masticatory myofascial pain) but overall evidence is limited and long-term benefit uncertain.

Bavarian et al. and Lawson trials summarized

PENS/TEAS: Perioperative TEAS and PENS demonstrate short-term analgesic and opioid-sparing effects in multiple trials; variable protocols and heterogeneity limit broad routine coverage absent defined indications and documentation.

Tan et al., Zhang et al. cited

inv-11: Summary coverage implications by indication

Evidence summary and inferred coverage implications by indication (informational):

Musculoskeletal pain and postoperative rehabilitation: TEAS/PENS and some ES modalities report short-term pain and functional gains in postoperative and musculoskeletal settings; however, heterogeneity, small samples, and limited duration of benefit (often <4 months) mean routine coverage should be limited to well-documented indications and adjunctive use.short-term benefit (<4 months)

Multiple systematic reviews and guidelines (NICE, AAOS) summarized

Postoperative analgesia/PONV/POI: TEAS/TEAS meta-analyses report reduced pain scores, opioid consumption and PONV within 24–72 hours post-op; evidence supports adjunctive perioperative use with documentation of protocol and short-term goals.benefit within 24–72 hours post-op

Wang et al., Chen et al. cited

Neuropathic pain / selected PNS indications:

inv-12: Extracted coverage-relevant evidence summaries

Extracted evidence summaries indicating when therapies showed benefit in cited studies (informational):

PENFS - pediatric functional GI disorders: Small RCTs and registries reported short-term reductions in abdominal pain, nausea and functional disability after 3–12 weeks of auricular PENFS; long-term controlled data are limited.short-term evidence

Kovacic et al., Chogle et al., Santucci et al. summarized

PNS - postoperative/neuropathic pain: Percutaneous and externally powered PNS studies report clinically meaningful responder rates and reductions in opioid use in selected cohorts, with some durability to 12+ months in case series; overall evidence is heterogeneous and often nonrandomized.select patients after conservative therapy

Fruh et al., Gilmore et al. summarized

PES/PEMF: Some small RCTs and systematic reviews in OA and CLBP show short-term pain/function improvements, but pooled evidence is inconsistent and insufficient to support routine use.

inv-13: PES/PEMF — Not supported by sufficient evidence

Coverage stance based on the available evidence:

PEMF/PES coverage stance: Evidence is insufficient to support routine use of PES/PEMF for treatment of chronic pain or musculoskeletal conditions; additional robust RCTs are required before routine coverage is appropriate.

Policy conclusion based on systematic reviews and meta-analyses

inv-14: ReActiv8 — Inconclusive evidence / conditional

Restorative neurostimulation (ReActiv8) — evidence context and conditional considerations:

ReActiv8 evidence context: Evidence includes a pivotal randomized sham‑controlled trial and single-arm studies showing efficacy signals in selected refractory mechanical CLBP populations, but overall evidence is limited by risk of bias, attrition, and small sample sizes; conclusions remain inconclusive.

Hayes/ECRI HTA summaries and trial publications (Gilligan et al.)

ReActiv8 trial population match: Trials enrolled adults with intractable CLBP despite >90 days of medical management and at least one course of physical therapy with documented multifidus dysfunction; device implantation and trial-like selection criteria should be documented to support medical necessity.>90 days medical management with at least one course of physical therapy

Pivotal trial inclusion criteria summarized in policy

inv-15: Implantable restorative neurostimulation (ReActiv8) — evidence context

Evidence context for implantable restorative neurostimulation:

ReActiv8 trial-population requirements: Patient has refractory mechanical CLBP despite >90 days of medical management and at least one attempt of physical therapy, and impaired multifidus control consistent with trial inclusion criteria.>90 days

Derived from trial enrollment criteria described in policy (Gilligan et al.)

ReActiv8 evidence limitations: Available studies include randomized and single-arm designs with high attrition in some cohorts and potential bias; benefits reported in cohorts but uncertainty remains regarding generalizability and durability.

Hayes and ECRI assessments summarized in policy

inv-16: Scrambler Therapy (ST) — evidence and coverage stance

Scrambler Therapy evidence summary and coverage stance:

Scrambler Therapy evidence: Systematic reviews and small RCTs report marginal short-term pain reductions in some chronic and neuropathic pain conditions, but evidence quality is low and heterogeneous; HTA reviews conclude evidence is insufficient for routine coverage.

Meta-analyses and HTA (Hayes, Karri, Jin et al.) summarized in policy

Guideline stance: Guidelines (ASCO, ESMO/EONS/EANO) do not recommend scrambler therapy for chemotherapy-induced peripheral neuropathy outside clinical trials; routine coverage is not supported without stronger evidence.

Guideline statements cited in policy

inv-17: Translingual stimulation (PoNS/TLNS) — evidence and coverage stance

Translingual stimulation (PoNS/TLNS) — evidence and coverage stance:

TLNS/PoNS evidence summary: RCTs combining PoNS/TLNS with targeted physical therapy show improvements in balance and gait in mmTBI and selected neurologic cohorts; both active and control arms often improved and generalizability is limited by sample size and trial conduct.

Ptito et al., Tyler et al., ECRI findings summarized in policy

Coverage implications: Coverage should be limited to device‑specific indications and require documentation that therapy is provided adjunctively with supervised targeted physical therapy and that patient selection matches trial populations.

Device labeling and De Novo approval context (PoNS) referenced in policy

inv-18: Device-specific clinical coverage considerations

Device-specific clinical coverage considerations (high-level requirements):

Device-specific requirements: Coverage depends on meeting device‑specific indications (e.g., PoNS for adjunctive PT in mmTBI/MS; ReActiv8 for refractory mechanical CLBP with multifidus dysfunction) and providing supportive documentation of prior therapies and trial‑like patient characteristics.

Device indications and regulatory notes summarized in policy

Documentation expectations: Documentation should include diagnosis consistent with device trials, prior conservative therapy attempts and durations, baseline functional/pain measures, and plan for supervised adjunctive therapy or device use as applicable.

Policy documentation requirements and trial entry criteria referenced

inv-19: ReActiv8 coverage considerations

Restorative neurostimulation (ReActiv8) — indication summary and coverage expectations:

ReActiv8 indication/coverage expectations: Indicated for intractable chronic low back pain associated with multifidus dysfunction in adults who have failed conservative therapy (medications and PT) and are not surgical candidates; coverage requires documentation that patient meets device labeling and trial‑like selection criteria.

PMA indication and device labeling referenced in policy

The policy identifies a set of electrical stimulation modalities considered unproven and not medically necessary because of insufficient evidence of efficacy. These explicitly include MENS, IFT (for musculoskeletal conditions or to facilitate healing of nonsurgical soft tissue injuries or fractures), PENS/PNT, PENFS, PNS, PES, PSFS/PNFS, restorative neurostimulation, scrambler therapy, and translingual stimulation for gait rehabilitation. Providers should assume these modalities are excluded from routine coverage unless high‑quality evidence or device‑specific indications are documented.

Multiple sections of the evidence review emphasize limitations in study quality, heterogeneity of protocols, small sample sizes, and short follow‑up, and explicitly call for larger, well‑designed randomized trials before broader adoption. Examples include NMES for swallowing and ICU‑related atrophy (evidence judged low to very low and needing larger trials), and PES/PEMF where current data are insufficient to support use for chronic pain. These evidence limitations imply that requests for coverage of modalities or indications without robust supportive data may be denied or require prior authorization with trial documentation.

For respiratory indications, the policy states that NMES has not been shown to replace conventional exercise‑based pulmonary rehabilitation. Systematic reviews found no consistent improvement in peak VO2 or health‑related quality of life, and authors concluded NMES should not be regarded as a replacement for pulmonary rehabilitation. When NMES is proposed for COPD‑related goals, documentation of prior or concurrent formal pulmonary rehabilitation is expected.

The policy references NICE guidance that recommends caution for NMES in oropharyngeal dysphagia and knee osteoarthritis: NICE advises that NMES for oropharyngeal dysphagia should be used only with special arrangements for clinical governance, consent and audit or in research, and that NMES should not be offered routinely for knee osteoarthritis because of insufficient evidence of benefit.

NICE guidance is cited regarding interferential therapy (IFT/IFC). NICE recommends that IFT should not be offered for knee osteoarthritis and chronic primary pain and concluded evidence is insufficient for use in low back pain with or without sciatica. Systematic reviews of IFC report inconsistent benefit and often no additional improvement when IFC is added to standard care.

NICE reviewed PENS and concluded there is insufficient evidence to support offering PENS for low back pain with or without sciatica; observed short‑term benefits were not sustained beyond four months. This guidance supports restricting routine coverage of PENS for chronic low back pain absent stronger long‑term data.

The policy summarizes reviews and HTA findings that evidence for percutaneous peripheral nerve stimulation (PNS) is limited and of low or very low quality for many indications. Hayes and ECRI assessments cited in the policy found insufficient or minimal support for several device‑specific PNS applications, indicating that PNS use generally requires careful patient selection and supportive documentation and may not meet routine coverage criteria.

Pulsed electrical stimulation (PES)/pulsed electromagnetic field (PEMF) therapies are described as having heterogeneous, small trials with mixed short‑term findings. The policy states that current evidence is insufficient to support the use of PES/PEMF for chronic pain, and this insufficiency supports treating these modalities as investigational or not medically necessary in routine practice.

Scrambler therapy (also called TEMPR/Calmare) is not supported by high‑quality evidence for chronic non‑cancer pain or chemotherapy‑induced peripheral neuropathy (CIPN). Guideline panels (ASCO, joint ESMO/EONS/EANO) do not recommend scrambler therapy for CIPN outside clinical trials, and systematic reviews rate the evidence as low or very low; routine coverage is therefore not supported.

The policy explicitly notes that FDA approval or clearance alone is not a basis for coverage. Regulatory status is informational; coverage determinations depend on clinical evidence, guideline recommendations, and applicable federal, state, or contractual benefit terms.

The policy cites TennCare Medicaid Chapter 1200‑13‑13‑.10 (Exclusions) as a reference for state‑specific exclusions that may apply to Tennessee Medicaid and CoverKids members. The revision history notes that the policy updated its reference link to the TennCare exclusions to ensure alignment with state requirements.

As part of the March 1, 2025 policy update, the coverage rationale was revised to update the reference link to TennCare Medicaid, Chapter 1200‑13‑13‑.10: Exclusions. This change reflects alignment with state Medicaid exclusions and was documented in the policy history.

Throughout the document the following modalities are referenced as unproven, limited, or not medically necessary for routine coverage: MENS, IFT/IFC, PENS/PENFS, TEAS, PNS, PSFS/PNFS, PES/PEMF, restorative neurostimulation (implantable), scrambler therapy, and translingual stimulation (PoNS/TLNS). The policy treats these modalities as excluded or investigational unless specific high‑quality evidence and device‑level indications support coverage.

The policy excerpts do not present a single blanket statement declaring all NMES‑type therapies medically necessary or not; instead, NMES is discussed in context‑specific terms. The document details supported NMES uses (e.g., disuse atrophy, perioperative rehabilitation) and notes areas where evidence is limited (e.g., swallowing disorders) and calls for further research rather than issuing a universal NMN declaration.

Reiterating guidance on pulmonary indications, the policy states NMES should be considered an adjunct to—but not a replacement for—conventional pulmonary rehabilitation. Systematic reviews found NMES did not consistently improve peak exercise capacity or HRQoL, supporting the stance that NMES alone is insufficient as a substitute for structured pulmonary rehab programs.

The policy summarizes that evidence for NMES in swallowing disorders is low to very low and inconclusive; systematic reviews recommend larger, well‑designed RCTs to define optimal protocols and long‑term effects. Separately, commercial neuropathic pain systems without published clinical studies (for example neo‑GEN‑Series per HTA reviews) lack evidence to support coverage.

Interferential current/IFT evidence is inconsistent and often shows no added benefit when combined with standard care. Systematic reviews and NICE guidance conclude IFT should not be offered routinely for various musculoskeletal indications; similarly, PENS reviews find low‑quality evidence and recommend that PENS not be used as a first‑line therapy for many musculoskeletal conditions.

The policy notes that PENS evidence is limited by heterogeneous protocols, risk of bias (particularly lack of blinding), and small study counts; although short‑term pain reductions are reported in some trials, the overall evidence quality restricts broad coverage and supports prior authorization and conservative‑first approaches.

Multiple HTAs and evidence reviews conclude the quality of PNS and PENFS evidence is low to very low for many indications. Given this uncertainty, the policy treats PNS applications as not established for routine coverage without robust patient selection criteria and stronger RCT data.

PES/PEMF modalities for chronic pain are characterized as having mixed short‑term study results but overall insufficient evidence to support routine clinical use. The policy indicates PES/PEMF should be considered investigational or not medically necessary pending more definitive controlled trials.

For chronic non‑cancer pain and chemotherapy‑induced peripheral neuropathy (CIPN), scrambler therapy is not supported by high‑quality evidence; guideline panels and systematic reviews have recommended against routine use outside of clinical trials. As a result, routine coverage for scrambler therapy in these indications is not supported.

The policy does not issue blanket 'not medically necessary' statements covering every electrical stimulation category; instead it sets coverage based on specific indications and the strength of the supporting evidence. Regulatory clearance or FDA approval is noted as informational only—coverage decisions are evidence‑ and indication‑based and may still exclude services despite device market authorization.

Procedure, DME, and Device Codes

Procedure CPT/UnlistedCPT

0278T	Transcutaneous electrical modulation reprocessing (eg , scrambler therapy) , each treatment session (includes placement of electrodes) pain.
0720T	Percutaneous electrical nerve field stimulation, cranial nerves, without implantation.
0783T	Transcutaneous auricular neurostimulation, set-up, calibration, and patient education on use of equipment.
63650	Percutaneous implantation of neurostimulator electrode array, epidural.
63655	Laminectomy for implantation of neurostimulator electrodes, plate/paddle, epidural.
63663	Revision including replacement; when performed, of spinal neurostimulator electrode percutaneous array(s) , including fluoroscopy, when performed.
63664	Revision including replacement; when performed, of spinal neurostimulator electrode plate/paddle(s) placed via laminotomy or laminectomy, including fluoroscopy, when performed.
63685	Insertion or replacement of spinal neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver.
64555	Percutaneous implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve).
64596	Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed; initial electrode array.

1–10 of 13

1/2

Durable Medical Equipment / HCPCSHCPCS

A4438	Adhesive clip applied to the skin to secure external electrical nerve stimulator controller, each.
A4543	Supplies for transcutaneous electrical nerve stimulator; for nerves in the auricular region, per month.
A4544	Electrode for external lower extremity nerve stimulator for restless legs syndrome.
A4556	Electrodes (apnea monitor), per pair.
A4557	Lead wires (e.g., apnea monitor), per pair.
A4593	Neuromodulation stimulator system, adjunct to rehabilitation therapy regime, controller.
A4594	Neuromodulation stimulator system, adjunct to rehabilitation therapy regime, mouthpiece, each.
A4595	Electrical stimulator supplies, 2 lead, per month (e.g., TENS, NMES).
E0720	Transcutaneous electrical nerve stimulation (TENS) device, two-lead, localized stimulation.
E0721	Transcutaneous electrical nerve stimulator for nerves in the auricular region.

1–10 of 17

1/2

Additional HCPCS/L Codes and Specialty Suppliesmixed

E1399	Durable medical equipment; miscellaneous.
L8678	Electrical stimulator supplies (external) for use with implantable neurostimulator; per month.
L8679	Implantable neurostimulator; pulse generator, any type.
L8680	Implantable neurostimulator electrode, each.
L8682	Implantable neurostimulator radiofrequency receiver.
L8685	Implantable neurostimulator pulse generator, single array, rechargeable, includes extension.
L8686	Implantable neurostimulator pulse generator, single array, nonrechargeable, includes extension.
L8687	Implantable neurostimulator pulse generator; dual array, rechargeable, includes extension.
L8688	Implantable neurostimulator pulse generator, dual array, nonrechargeable, includes extension.
S8130	Interferential current stimulator, 2 channel.

1–10 of 11

1/2

FES device examples verified for E0770HCPCS

E0770 (device list)

Only FES devices verified by CMS PDAC to be reported with E0770: Odstock ODFS Pace FES System (Odstock Medical/Boston Brace); NESS L300 and H200 devices (Bioness); WalkAide (Innovative Neurotronics); Deluxe Digital Electronic Muscle Stimulator (Drive Medical).

No explicit codes in these chunksmixed

No codes listed

No explicit CPT/HCPCS/ICD codes in this sectionmixed

No codes listed

No explicit codes in this excerptmixed

No codes listed

Device product codes and regulatory identifiersmixed

Product Code GZI	FES devices (FDA product code reference)
Product Code IPF	NMES devices (FDA product code reference)
Product Code LIH	Interferential Therapy (IFT) devices (FDA product code reference)
Product Code (PES device search)	Pulsed Electrical Stimulation devices (FDA product code reference)
Product Code NHI	PENS devices (FDA product code reference)
Product Code PZR	PSFS / PNFS devices (FDA product code reference)
Product Code GZJ	TENS / MENS / Scrambler Therapy device product code
Product Code QLK	ReActiv8 restorative neurostimulation system product code
PoNS De Novo	Portable Neuromodulation Stimulator (PoNS) regulatory pathway note

Health technology assessment sources (no billing codes in this section)mixed

No codes listed

Provider Actions, Prior Authorization, and Documentation

Note

Applicable codes (for reference/prior authorization review)

The lists of applicable procedure, supply, and implant codes below are provided for reference and may be used during prior authorization review. Inclusion of a code does not guarantee coverage or payment; coverage is determined by federal, state, or contractual requirements.

Key CPT / HCPCS / L-codes: 0278T, 0720T, 0783T, 63650, 63655, 63663, 63664, 63685, 64555, 64596-64598, 64999
Key HCPCS/supply codes: A4438, A4543-A4544, A4556-A4557, A4593-A4595, A4594, E0720-E0731, E0743-E0745, E0764, E0770
Durable/implantable device codes: E1399, L8678-L8688, S8130-S8131

Prior Authorization

Consider prior authorization for inpatient/ICU NMES

Prior authorization should be considered for inpatient or intensive care unit (ICU) use of NMES given limited, heterogeneous evidence and variable study settings; verify medical necessity and documentation supporting ICU/acute-care application.

Consider PA when NMES is provided while patient is on mechanical ventilation or in ICU

Required Conservative Therapy and Prior Treatment

inv-146: Document prior or concurrent pulmonary rehab when proposing NMES for COPD

When NMES is proposed for COPD patients, document prior or concurrent participation in a conventional pulmonary rehabilitation program:

Document pulmonary rehab: Prior or concurrent enrollment in a supervised pulmonary rehabilitation program (exercise-based) should be documented when NMES is proposed for COPD-related functional goals; NMES is adjunctive and should not replace standard pulmonary rehab.

Wu et al. and Gutierrez-Arias conclusions summarized in policy

inv-147: Implied recommendation to attempt standard conservative measures before/alongside ES modalities

Implied recommendation to attempt standard conservative measures before or alongside electrotherapy modalities:

Attempt standard conservative measures: Conservative nonpharmacologic therapies (exercise, hot packs, standard physiotherapy, multidisciplinary rehabilitation) should be tried prior to or concurrently with electrotherapy modalities where guideline-recommended.

Frequency, Duration, and Supply Limits

NMES session examples from trials

Typical trial regimenEarly post-operative NMES regimens in trials were delivered twice daily (e.g., initiated 48 hours after TKA with twice-daily sessions at maximum tolerable intensity for 15 contractions).

Session intensity/durationTrials reported sessions at maximum tolerable intensity with defined contraction counts (example: 15 contractions per session in a TKA trial).

Timing relative to surgeryNMES started early post-op (example: initiated 48 hours after total knee arthroplasty in cited RCT).

Outcomes timingOutcomes were assessed at multiple post-op timepoints (e.g., 3.5, 6.5, 13, 26, and 52 weeks) to capture short- and longer-term effects.

Indication contextNMES used as adjunct to standard rehabilitation to attenuate early postoperative quadriceps weakness and improve early functional outcomes.

Imaging and Objective Assessment Requirements

Documentation Required

Imaging as indicated for spinal neurostimulator procedures

Spinal neurostimulator implantation and revision CPT codes reference fluoroscopy when performed; image guidance is used as indicated by procedure code descriptions.

Codes such as 63663 and 63664 include fluoroscopy when performed

Documentation Required

NMES outcome assessment — imaging not mandated

NMES outcome assessments in trials used objective functional measures (strength testing, MRI muscle volume) but no mandated imaging requirements for coverage are specified.

Provide objective functional or imaging outcomes when available; imaging is not routinely required

Documentation Required

MENS — imaging used in studies but not required

Definitions and Modality Descriptions

Electrical stimulation devices deliver direct, alternating, pulsating, or pulsed waveforms via surface, percutaneous, or implanted electrodes to produce muscle contraction, modulate pain, or effect other therapeutic targets. Modalities vary by mechanism and depth of stimulation and include transcutaneous NMES/FES for muscle rehabilitation, percutaneous and implanted nerve stimulators for pain modulation, and noninvasive approaches such as MENS, IFT, PES/PEMF, scrambler therapy, and translingual stimulators. Device type and intended physiologic effect determine the clinical application and the nature of evidence required to support coverage.

Electrical stimulator — definition

General definitionElectrical stimulators provide direct, alternating, pulsating, or pulsed waveform energy via electrodes (indwelling, implanted, or surface) to produce muscle response or analgesia by controlling pulse parameters such as length, frequency, amplitude, and triggering modes.

Electrode typesElectrodes may be indwelling, implanted, transcutaneous, or surface-based depending on modality and clinical application.

Primary usesDevices are used to exercise muscles, demonstrate muscular responses, relieve pain, treat incontinence, and provide diagnostic/test measurements.

Not Covered / Excluded Therapies

The policy lists modalities that are not covered for routine use due to insufficient evidence: IFT/IFC, MENS, PENS/PENFS/PNT, PNS, PSFS/PNFS, PES/PEMF, restorative neurostimulation (implantable), scrambler therapy, and translingual stimulation (PoNS/TLNS). It also identifies NMES standalone use as a replacement for pulmonary rehabilitation and novel commercial devices lacking published studies as non‑covered or investigational. Providers should consult the policy and applicable state exclusions (e.g., TennCare Chapter 1200‑13‑13‑.10) when determining coverage for these modalities.

Policy Revision History

2025-03-01policy_revisionLatest

Coverage Rationale updated with revised TennCare Medicaid Chapter 1200-13-13-.10 exclusions link; Description of Services, Clinical Evidence, FDA, and References sections updated to reflect current information.

Policy Summary

PayerUnitedHealthcare

PolicyElectrical Stimulation for the Treatment of Pain and Muscle Rehabilitation (for Tennessee Only)

Policy CodePolicy CSO36TNX

Change TypeReference & supporting information updates

Effective DateMar 1, 2025

Next Review Date

SourceLink

On This Page

Listed as unproven in policy

Unproven modalities: Percutaneous peripheral nerve stimulation (PNS).

Listed as unproven in policy

Unproven modalities: Pulsed electrical stimulation (PES) / pulsed electromagnetic field (PEMF).

Listed as unproven in policy

Unproven modalities: Peripheral subcutaneous field stimulation (PSFS/PNFS).

Listed as unproven in policy

Unproven modalities: Restorative neurostimulation (implantable devices such as ReActiv8).

Listed as unproven in policy excerpt

Unproven modalities: Scrambler Therapy (ST).

Listed as unproven in policy

Unproven modalities: Translingual stimulation (TS/PoNS/TLNS) for gait/rehabilitation outside described investigational/limited indications.

Listed as unproven in policy

short-term postoperative benefit (24–72 hrs)

Tan et al., Zhang et al., Chen et al. cited

PENFS - pediatric DGBI: Auricular PENFS registries and small RCTs report short-term improvements in adolescents with DGBI, but evidence is limited by lack of controls and short follow-up.observational/limited RCT evidence

Chogle et al., Kovacic et al. cited

Some guideline groups endorse PENS for selected neuropathic conditions (e.g., PDN); PNS and percutaneous PNS show signal for benefit in selected post-op or neuropathic cohorts but evidence quality varies and selection after conservative therapy is typical.

select patients after conservative therapy

AAN/AANEM/AAPMR guidance and PNS studies summarized

PENFS for pediatric DGBI: Observational registries and small trials report symptom and functional improvements in pediatric DGBI populations after auricular PENFS, but controlled, long-term evidence is limited.observational evidence only

Chogle et al., Kovacic et al. cited

insufficient evidence

Yang et al., Markovic et al., Newberry et al. summarized

Request documentation of indication, location of service, and rationale for inpatient/ICU delivery

Prior Authorization

Prior authorization likely for investigational / limited‑evidence electrostimulation

Electrotherapy and neuromodulation approaches with limited or emerging evidence (for example certain PNS devices, investigational stimulators, PEMF/PES, scrambler therapy, and novel implantable systems without conclusive effectiveness data) are likely to require prior authorization and may be subject to denial if evidence is insufficient.

Prior authorization likely for investigational or limited‑evidence electrostimulation (ES) therapies
May require submission of peer‑reviewed evidence, HTA/Evidence Assessment reports, and prior treatment history

Prior Authorization

Prior authorization recommended for PENS / TEAS

Percutaneous electrical nerve stimulation modalities such as PENS and transcutaneous acupoint stimulation (TEAS) have mixed evidence; prior authorization is recommended to ensure appropriate candidate selection and to collect documentation of prior conservative care and expected treatment parameters.

Recommend PA for PENS/TEAS to verify indication, duration, and prior therapies
Request trial data or documentation of inadequate response to conservative measures

Prior Authorization

Prior authorization recommended for percutaneous stimulation

Percutaneous stimulation procedures (including ultrasound‑guided PENS and peripheral nerve field stimulation) often require practitioner expertise and may have variable evidence; prior authorization is recommended to confirm procedural intent, target nerve, and pre-procedure conservative therapy.

PA recommended for percutaneous stimulation claims (provide indication, target nerve, and prior conservative treatments)
When used as alternative to surgery (e.g., carpal tunnel, CTS), include trial and outcome documentation

Prior Authorization

Prior authorization recommended for PNS and device implantation

Peripheral nerve stimulation (PNS) and implantation of neurostimulation devices (including lead and pulse generator insertion) typically require prior authorization to confirm conservative therapy failure, reviewer‑requested diagnostic testing, and plan‑specific coverage for implants.

PA recommended for PNS device implantation (CPT codes 64555, 64596-64598 and related L-codes)
Require documentation of prior conservative care and rationale for implantation

Prior Authorization

Prior authorization for implantable restorative neurostimulation

Implantable restorative neurostimulation systems (for example ReActiv8) require prior authorization due to specialized indications, claims for implants, and mixed evidence; authorization should confirm conservative care failure and device‑specific eligibility criteria.

PA required for implantable restorative neurostimulation (implant codes and L‑codes apply)
Submit documentation: duration and type of conservative therapy, pain/disability scores (e.g., ODI, VAS), imaging/physiologic evidence of multifidus dysfunction, and prior therapy dates

Prior Authorization

Prior authorization for device‑based therapies

Device‑based neuromodulation therapies (implantable and some extended percutaneous systems) should be prior‑authorized to ensure appropriate patient selection, device FDA status, and submission of supporting clinical evidence such as HTA and evidence reviews.

PA recommended for device implantation and for long‑term device‑based therapies
Include HTA/Evidence Assessment citations when available (ECRI, Hayes) to support coverage determination

Note

HTA and evidence citations relevant to authorization

Health technology assessments and evidence reviews (for example ECRI and Hayes reports) are relevant documents to include with authorization requests for neuromodulation and electrotherapy devices and may influence the authorization decision.

Relevant HTA citations: ECRI ReActiv8 and PoNS assessments; Hayes EARB reports on PNS, scrambler therapy, and other devices
Attach HTA / evidence assessment documents or citations when submitting prior authorization

Prior Authorization

Prior authorization and plan verification

Before authorizing services, verify the member's specific plan coverage, federal/state/contractual mandates, and any plan exclusions. Prior authorization decisions must reference applicable benefit terms.

Providers and reviewers must check member plan, state and federal requirements prior to authorization
PA does not supersede contractual or regulatory exclusions

Denial Risk

Evidence insufficiency may trigger non‑coverage

Evidence insufficiency or low‑quality, heterogeneous data for some modalities (for example certain IFT/IFC, PES/PEMF, scrambler therapy, novel PNS indications) may lead to non‑coverage or denial. Reviewers should consider the quality, size, and applicability of studies when making determinations.

Documented insufficient evidence may trigger non‑coverage decisions
Request higher‑quality trial data or HTA evidence when available

Denial Risk

IFC and other weak‑evidence modalities may risk denial

Interferential current (IFC), pulsed electromagnetic field (PEMF)/PES, and other modalities with weak or inconsistent evidence may be at risk for denial if submitted without strong supporting documentation.

IFC and similar modalities with weak evidence: risk of denial if clinical benefit is not demonstrated
When submitting, include trial data, objective measures, and rationale for use

Note

FDA approval informational note

FDA approval status is informational only. FDA clearance or approval of a device does not alone establish coverage; coverage decisions are based on clinical evidence and benefit terms.

Examples: ReActiv8 (PMA June 16, 2020), PoNS (De Novo March 25, 2021) — FDA status should be cited but is not determinative for coverage

Documentation Required

Reference required for TENS / FES criteria

When criteria reference use of TENS or FES, include the specific coverage/clinical criteria or external reference (for example InterQual Durable Medical Equipment criteria) with the authorization request.

Reference required: InterQual CP: Durable Medical Equipment; Transcutaneous Electrical Nerve Stimulation (TENS) for medical necessity criteria
Include product model, lead configuration, and intended anatomical target when submitting

Documentation Required

Clinical outcome documentation (baseline and follow‑up measures required)

Provide clinical outcome documentation to support medical necessity and authorization decisions. Objective baseline and follow‑up measures strengthen the request and facilitate utilization review.

Document baseline and follow‑up functional measures (examples: VAS, ODI, Oswestry, HSS, KSS, gait/balance scores, swallowing scales)
Record timing of stroke or injury and prior therapy details when applicable (onset dates, therapy types, duration)

Documentation Required

Document stroke timing and prior therapy

When treating post‑stroke dysphagia or other neurologic rehabilitation indications, document stroke timing, prior and concurrent therapies, and objective swallowing or functional assessments to support use of NMES or related therapies.

Provide date of stroke onset, prior swallowing therapy duration and response, and rationale for adding NMES
Include validated swallowing assessments and measures of improvement over specified treatment intervals

Documentation Required

Documentation of baseline and follow‑up functional measures

Authorization requests should include objective baseline and serial follow‑up outcome measures appropriate to the indication to demonstrate clinical benefit (for example strength testing, walking distance, validated questionnaires).

Examples of baseline and follow‑up measures: quadriceps strength, 6‑minute walk distance, IKES, UWS/MWS, ODI, VAS, HSS/KSS scores, SOT/DGI for balance
State dates and numerical results for each assessment point submitted

Documentation Required

Suggested documentation elements from trials

When available, include suggested trial documentation elements drawn from clinical trials and registries to support durability and effectiveness claims for neuromodulation therapies.

Suggested elements: indication, prior conservative therapies with dates, baseline validated outcome scores, trial stimulation parameters and duration, device compliance logs, adverse events, and follow‑up scores at prespecified intervals
For implantable devices include device model, lead placement details, intraoperative findings, and trial stimulation results if a temporary trial was performed

Documentation Required

Documentation for restorative neurostimulation

Specific documentation requirements apply for restorative neurostimulation implants: confirm prior conservative management, objective baseline disability/pain scores, imaging or physiologic evidence of multifidus dysfunction, device implantation details, and longitudinal follow‑up outcomes.

Required: documentation of failed conservative care (physical therapy, medications), duration (>90 days where applicable), baseline ODI/VAS, imaging/physiologic evidence of multifidus impairment, operative and device details, and post‑implant outcome measures at standard intervals
Include any device explant or serious adverse event reports

Documentation Required

Supporting clinical documentation

Supporting clinical documentation such as HTA reports, RCT results, registries, and device‑specific studies should be attached to prior authorization requests when available to substantiate benefit and safety claims.

Attach relevant HTA/Evidence Assessment (ECRI, Hayes) and key peer‑reviewed studies (e.g., ReActiv8 RCT, PoNS trials, PNS multicenter series) when submitting PA
Include registry follow‑up data if claiming long‑term benefit

Note

Supportive guideline references

Include guideline and position statement references in authorization submissions to align requests with recognized clinical recommendations and to clarify recommended use and limitations.

Support requests with applicable guideline citations (for example NICE guidance on NMES/PENS, AHA/ASA stroke rehab statements, AAOS knee OA guideline comments on PENS)
If guideline advice recommends research‑only use or special arrangements (e.g., NICE IPG634), include justification and governance plan

Note

Providers should check applicable federal, state, and contractual requirements

Providers must verify and comply with applicable federal, state, and contractual coverage requirements before submitting authorization requests; coverage decisions are governed by those requirements when conflicts arise.

Check federal/state/contractual mandates and any plan exclusions prior to requesting authorization
UnitedHealthcare uses third‑party tools (e.g., InterQual) to assist in administering benefits — include referenced criteria where applicable

ACP guidance and comparative trials referenced in policy

inv-148: document trial of recommended non-pharmacologic therapy where applicable

Document trials of recommended nonpharmacologic therapy where applicable to support medical necessity for electrotherapy interventions:

Document trial of non-pharmacologic therapy: Record details of prior nonpharmacologic therapy (type, duration, response) such as exercise programs, multidisciplinary rehabilitation or PT when seeking electrotherapy interventions.

ACP guideline context cited in policy

inv-149: Conservative-first approach implied by evidence and guideline statements.

A conservative‑first approach is implied by guideline and evidence statements for many electrotherapy modalities:

Conservative-first approach: For modalities such as PENS/PENFS/TEAS and PNS, trials and guideline reviews suggest these should not be first‑line therapies; document failure or inadequate response to conservative care before considering these modalities.

NICE guidance and PENS/PENS reviews summarized

inv-150: Document prior conservative treatments and failure prior to considering PNS

Document prior conservative treatments and failure prior to considering percutaneous peripheral nerve stimulation (PNS):

PNS prior conservative care: Provide documentation of prior multimodal or conservative care (medications, physical therapy, interventional or rehabilitative measures) and lack of adequate response before PNS is considered.

PNS studies typically enrolled patients after failure of noninvasive therapies

inv-151: Documented failure of conservative care prior to considering implantable restorative neurostimulation.

Documented failure of conservative care is required before considering implantable restorative neurostimulation:

Restorative neurostimulation conservative care: Document >90 days of medical management and at least one course of physical therapy with inadequate response prior to consideration of implantable restorative neurostimulation (ReActiv8), consistent with trial entry criteria.> 90 days

Derived from ReActiv8 trial enrollment criteria (Gilligan et al.) as summarized in policy

inv-152: Documented failure of conservative care prior to considering implantable restorative neurostimulation

Restorative neurostimulation trials required prior conservative management:

Restorative neurostimulation conservative requirement: Trials specified >90 days medical management and at least one attempt of physical therapy prior to enrollment; similar documentation should support medical necessity requests for implantation.>90 days medical management with at least one course of physical therapy

Trial inclusion criteria summarized in policy

inv-153: Documentation of prior conservative therapy attempts is required to support medical necessity.

Documentation of prior conservative therapy attempts is required to support medical necessity for device-based neuromodulation and adjunctive therapies:

Documentation of prior conservative therapy: Provide records of prior physical therapy, medication trials, duration and response; for adjunctive devices (e.g., PoNS) document prior supervised PT and plateau in recovery as applicable.

Policy documentation guidance and trial descriptions referenced

Frequency limits — general note

Policy frequency limits providedNo explicit coverage frequency limits are specified in the cited policy excerpts; trial regimens are described but formal payer limits are not given.

Heterogeneous protocolsStudies report broad heterogeneity in NMES delivery (session duration, intensity, days of therapy and sessions per week), limiting a single standardized frequency in policy text.

Outcome-based documentationTrials used multiple assessment timepoints and objective outcome measures; documentation of protocol and response recommended in clinical records when requesting coverage.

PENS / PENFS examples from studies

PENS for CTS exampleOne RCT used ultrasound-guided PENS targeting the median nerve once weekly for 3 weeks for carpal tunnel syndrome, with follow‑up at 1, 3, 6 and 12 months.

PENFS registry exampleMulticenter registries and observational PENFS studies commonly applied once-weekly sessions for up to 12 weeks (examples in pediatric DGBI registries with weekly therapy durations).

Protocol variabilityPENS/PENFS study protocols vary widely (single session to multiple weekly sessions), so frequency should be referenced to the specific trial protocol when documenting medical necessity.

Percutaneous PNS lead duration in studies

Lead dwelling durationPercutaneous PNS leads in trials were typically left in place for treatment courses up to 60–90 days (examples: 8 weeks in randomized trials; 60-day courses reported in multicenter series).

Daily use during courseSome percutaneous PNS protocols instructed device use for multiple hours per day (e.g., 6–12 hours/day during a 60-day treatment period in case series).

Follow-up windowStudies included follow-up visits during and after lead removal (e.g., weekly during treatment and extended follow-up to 12 months in some trials).

Implantable restorative neurostimulation — frequency/duration notes

Implantable restorative neurostimulation scheduleImplantable restorative neurostimulation trials (e.g., ReActiv8) delivered stimulation sessions per device programming after implantation, but the policy excerpts do not specify a standardized frequency or session duration for clinical use.

Trial stimulation regimenIn the ReActiv8 randomized trial participants received therapeutic or low‑level sham stimulation twice daily during the blinded phase (example: twice daily sessions for 120 days in the RCT).

Post‑implant programingStimulation is typically programmed post‑implant and delivered in scheduled sessions per device labeling; specific payer frequency limits were not provided in the excerpts.

Microcurrent (MENS) trials used musculoskeletal ultrasound for outcome assessment in research settings, but imaging is not mandated for clinical coverage.

Ultrasound findings cited as study outcomes; not required for routine authorization

Documentation Required

PENS for CTS — ultrasound used in trial (not universally required)

Ultrasound guidance was used in a PENS trial for carpal tunnel syndrome (median nerve targeting); imaging guidance is study‑specific and not broadly mandated for coverage.

If ultrasound‑guided technique is used, document the guidance and provider expertise

Documentation Required

PENFS (research contexts) — imaging not required

PENFS evidence is primarily research‑based; neuroimaging and other imaging were used in some studies for biomarkers, but imaging is not required for routine clinical use.

Indicate research context and any imaging used when submitting trial‑based requests

Documentation Required

Implantable restorative neurostimulation — no specific imaging specified

Implantable restorative neurostimulation trials do not specify routine imaging requirements for coverage; document device implantation and any device‑label recommended testing if available.

Trials programmed stimulation post‑implant and used clinical outcome measures rather than mandated imaging

Documentation Required

ReActiv8 implantation — imaging/physiological testing as indicated by labeling

ReActiv8 implantation may require imaging or physiological testing to demonstrate multifidus dysfunction as indicated by device labeling; include such evidence when available.

Provide imaging or physiological test results if used to demonstrate multifidus dysfunction per device indication

Documentation Required

Percutaneous stimulation — follow guideline/device imaging guidance when applicable

Guidelines and interventional procedure guidance cited for percutaneous electrical nerve stimulation/neuromodulation may include recommendations for imaging guidance; follow guideline or device labeling guidance as applicable.

Document any imaging guidance used (e.g., ultrasound) and rationale in authorization requests

Interferential Therapy (IFT)

Modality descriptionInterferential Therapy (IFT) delivers two medium‑frequency pulsed currents via skin electrodes that cross to produce a low‑frequency current theorized to penetrate deeper tissues and modulate pain and healing.

Therapeutic rationaleIFT is proposed to prompt endorphin release, stimulate parasympathetic fibers, increase blood flow and reduce edema for musculoskeletal pain and soft‑tissue healing.

Evidence contextSystematic reviews report inconsistent results with possible short‑term pain relief versus placebo but limited additional benefit when added to standard care; NICE guidance recommends against routine offering for several indications.

MENS — definition

DefinitionMicrocurrent Electrical Nerve Stimulation (MENS) delivers microampere‑level currents (sub‑sensory) intended for pain relief and wound healing; currents are much lower than TENS and typically not perceptible to users.

Regulatory noteMENS devices are often categorized with TENS for regulatory purposes but operate at substantially lower current amplitudes and different mechanisms of action.

Evidence summaryAvailable RCTs and meta-analyses are small and heterogeneous; some reviews report modest short‑term pain reductions but overall evidence is limited and inconclusive for most indications.

NMES — definition

DefinitionNeuromuscular Electrical Stimulation (NMES) uses transcutaneous electrical currents to evoke muscle contractions to promote reinnervation, prevent or treat disuse atrophy, relax spasms, and improve voluntary muscle control during rehabilitation.

Clinical applicationsNMES is used for disuse atrophy, adjunctive rehabilitation after TKA/ACL and in some post‑stroke and ICU settings when nerve supply to muscle is intact.

Protocol variabilityNMES protocols in studies vary in intensity, session frequency and duration; early post‑operative regimens (e.g., twice daily) showed the most pronounced short‑term benefits in some trials.

PENS / PENFS — definition

DefinitionPercutaneous electrical nerve stimulation (PENS) and percutaneous electrical nerve field stimulation (PENFS) use percutaneous needle electrodes connected to an external stimulator to modulate nerve hypersensitivity or broader tissue fields (auricular PENFS).

Technique distinctionPENS targets specific peripheral nerves via needle electrodes near the painful area; PENFS often targets broader fields such as auricular bundles to modulate central pathways.

Typical trial regimensExamples include ultrasound‑guided PENS once weekly for 3 weeks (CTS RCT) and PENFS applied once weekly for up to 12 weeks in registries for pediatric DGBI; overall protocols are heterogeneous.

PNS / PSFS — definition

DefinitionPeripheral Nerve Stimulation (PNS) implants or places electrodes near peripheral nerves to deliver electrical impulses that disrupt pain transmission for chronic or postoperative pain.

PSFS/PNFS distinctionPeripheral Subcutaneous Field Stimulation (PSFS/PNFS) implants arrays in subcutaneous tissue to stimulate cutaneous nerve endings across a painful field when a discrete nerve target is not defined.

Clinical contextEvidence base includes small RCTs, case series and observational studies; some recent trials use percutaneous temporary leads left for defined treatment durations (e.g., 60 days).

Restorative neurostimulation — definition

DefinitionRestorative neurostimulation is a minimally invasive implanted therapy that stimulates the lumbar multifidus via leads placed adjacent to the medial branch of the dorsal ramus to rehabilitate neuromuscular control in chronic mechanical low back pain.

Device exampleReActiv8 Implantable Neurostimulation System is an example of restorative neurostimulation and has received PMA/approval for specified indications.

Intended effectDesigned to restore multifidus muscle function as a rehabilitative approach rather than solely palliative pain modulation; device programming and scheduled stimulation are performed post‑implant.

Pulsed Electrical Stimulation (PES) / PEMF

DefinitionPulsed Electrical Stimulation (PES) and Pulsed Electromagnetic Field (PEMF) therapies apply time‑varying electrical or electromagnetic fields noninvasively, hypothesized to facilitate bone and cartilage repair and modulate inflammatory cell function.

Mechanistic noteElectrostatic and electrodynamic fields may alter cellular signaling in chondrocytes and osteoblasts, potentially affecting tissue healing, but clinical evidence is heterogeneous.

Evidence contextSystematic reviews conclude evidence is insufficient to support routine use for chronic pain; some small RCTs report short‑term benefits in OA/CLBP but heterogenous protocols limit conclusions.

Restorative Neurostimulation (alternate entry)

Restorative neurostimulation (alt)An implanted neuromuscular stimulator intended to activate multifidus muscles to treat refractory mechanical chronic low back pain associated with impaired multifidus control; therapy is delivered per device programming after implantation.

Evidence summaryRandomized and single‑arm trials report efficacy signals in selected refractory CLBP populations after conservative care, but studies have limitations (attrition, risk of bias).

Clinical prerequisitesTrials enrolled patients who had failed >90 days of medical management and at least one course of physical therapy prior to implantation.

Scrambler Therapy — definition

DefinitionScrambler Therapy (ST) is a noninvasive transdermal neuromodulation approach delivering continuously changing, variable nonlinear waveforms via skin electrodes to present 'non‑pain' information to painful dermatomes for symptomatic relief of chronic pain.

Treatment course examplesTypical reported courses in trials were daily sessions of 30–50 minutes over 10 working days (e.g., 10 consecutive weekdays) with follow‑up up to months post‑treatment.

Evidence contextSystematic reviews and RCTs are small and heterogeneous; guideline panels recommend against routine use for some indications (e.g., CIPN) outside clinical trials.

TENS — definition

DefinitionTranscutaneous Electrical Nerve Stimulation (TENS) delivers electrical current via surface electrodes to decrease pain perception by inhibiting afferent pain impulses and/or stimulating endogenous analgesic mechanisms.

Device varietyTENS devices include two‑lead and multi‑lead systems and are commonly represented by HCPCS E0720/E0730 for DME reporting; many commercial products are available.

Clinical roleUsed for symptomatic pain relief across multiple conditions; evidence and guideline recommendations vary by indication and modality compared to other electrotherapies.

Translingual Stimulation (TLS/PoNS) — definition

DefinitionTranslingual Stimulation (TLS/TLNS/PoNS) is a noninvasive neuromodulation approach that delivers electrical stimulation to the tongue to activate trigeminal and facial afferents, used adjunctively with targeted physical therapy to enhance neuroplasticity for balance and gait rehabilitation.

Device/regulatory noteThe PoNS device received De Novo authorization (PoNS De Novo, 2021) and trials combined PoNS with supervised PT in mmTBI and MS cohorts.

Evidence summaryRCTs show improvement in balance and gait when TLNS is combined with physical therapy, but both high‑ and low‑frequency arms often improved and generalizability is limited by sample size and trial design variability.

NMES (alternate) — definition and use

Alternate NMES descriptionNMES applied to muscles or nerves evokes contractions to improve strength, motor control, or swallowing function when nerve supply is intact; often used alone or combined with conventional therapy in rehabilitation trials.

Specific applicationsExamples include quadriceps NMES after TKA, dorsiflexor stimulation post‑stroke, and suprahyoid muscle stimulation for dysphagia in varied trial durations (2–12 weeks).

Outcome measuresTrials measured muscle strength, functional performance, AROM, walking speed, and patient‑reported outcomes at multiple follow‑up intervals to assess benefit.

CCFES — definition

CCFES definitionContralaterally Controlled Functional Electrical Stimulation (CCFES) is a form of FES where movement of the unaffected limb controls stimulation of the affected limb to assist recovery (used in post‑stroke upper limb rehabilitation studies).

Comparison to NMESTrials comparing CCFES to conventional NMES report improvements in some motor measures but mixed between‑group differences; protocols often used daily or multiple weekly sessions over weeks to months.

Clinical contextCCFES is investigated as an adjunct to routine rehabilitation for subacute and chronic stroke motor recovery, with variable trial durations and intensities.

NMES (alternate) — definition and evidence

NMES definition (alternate)NMES delivered transcutaneously elicits muscle contraction for prevention of disuse atrophy and promotion of voluntary control; studied across ICU, postoperative and neurologic rehabilitation settings.

Evidence characteristicsSystematic reviews/meta‑analyses summarize small‑to‑moderate effects on muscle strength and size and mixed functional outcomes; heterogeneity in protocols and risk of bias are common limitations.

Use recommendationUsed as an adjunct to standard rehabilitation rather than a replacement, particularly in early postoperative or ICU settings where early application showed more pronounced short‑term effects.

IFT / IFC — definition

IFT/IFC definitionInterferential current therapy (IFC/IFT) uses medium‑frequency alternating currents via surface electrodes to produce low‑frequency effects thought to penetrate deeper tissues for musculoskeletal pain relief.

Evidence noteSystematic reviews report possible immediate post‑treatment pain reduction but generally no added benefit when combined with standard care; NICE advises against routine offering for several indications.

Typical session characteristicsTrials vary widely in session duration, frequency and total treatment weeks; protocols are heterogeneous across indications.

Electrical stimulation modalities network

Modalities networkNetwork meta‑analyses compare multiple electrical stimulation modalities (e.g., h‑TENS, l‑TENS, NMES, IFC, PES, NIN) to rank effectiveness for conditions such as knee osteoarthritis, showing heterogeneous results and modality‑specific rankings.

InterpretationComparative networks often identify different modalities as 'most probable' options for specific outcomes (example: IFT ranked promising for knee OA in one network), but heterogeneity limits definitive recommendations.

Policy implicationDevice/modality selection should reference condition‑specific evidence and documented trial protocols when seeking coverage or prior authorization.

MENS / microcurrent therapy (MCT)

MENS / MCT definitionMicrocurrent therapy (MENS/MCT) uses very low amplitude microcurrent (microampere range) delivered transcutaneously for pain and tissue healing with sub‑sensory stimulation.

Evidence summarySmall RCTs and meta‑analyses report modest short‑term pain reductions in selected conditions (e.g., masticatory myofascial pain), but overall evidence is limited and trial protocols are small and heterogeneous.

Regulatory contextMENS devices may be categorized with TENS for regulatory convenience despite different operating currents and clinical effects.

IFC / IFT — summary

IFC / IFT summaryInterferential current therapy (IFC/IFT) is a medium‑frequency surface modality evaluated across musculoskeletal conditions; systematic reviews find inconsistent benefit, often short‑term and protocol‑dependent.

Clinical guidanceNICE and other guideline statements discourage routine offering for several indications (knee OA, chronic primary pain, low back pain) due to insufficient consistent evidence.

Trial characteristicsRCTs and meta‑analyses show variable methodological quality and short follow‑up durations, limiting assessment of sustained benefit.

PENS / TEAS — definition

PENS / TEAS definitionPENS (percutaneous electrical nerve stimulation) and TEAS (transcutaneous electrical acupoint stimulation) deliver electrical stimulation via needle or acupoint‑based electrodes to modulate pain and endogenous analgesic mechanisms.

Perioperative evidenceSystematic reviews of TEAS/PENS report reductions in short‑term postoperative pain and opioid consumption, with heterogeneity in acupoints, frequencies and timing across studies.

Typical trial dosingMany PENS studies included single sessions or short-course protocols; TEAS perioperative trials commonly assessed outcomes within the first 24–72 hours post‑op.

PENS/PENFS/TEAS/TENS — combined definitions

Combined modalities descriptionPENS/PENFS/TEAS/TENS encompass minimally invasive (percutaneous) and transcutaneous electrical approaches delivering stimulation to nerves or acupoints to modulate pain and related symptoms.

Scope of useThese modalities are evaluated across perioperative analgesia, musculoskeletal rehabilitation, neuropathic pain and pediatric DGBI, with heterogeneous protocols and evidence quality.

Documentation implicationTrial protocols (frequency, duration, targets) should be documented when requesting coverage due to variable evidence and short‑term effect profiles.

PENFS — definition

PENFS definitionPercutaneous electrical nerve field stimulation (PENFS) typically uses auricular or cranial peripheral bundles to stimulate broad tissue fields (e.g., auricular PENFS for pediatric DGBI), often delivered via percutaneous mini‑leads or field devices.

Evidence characteristicsPENFS studies include registries and small RCTs showing short‑term symptom improvements in pediatric functional abdominal pain and adult fibromyalgia, but controls and long‑term data are limited.

Typical dosing examplesReported regimens include once‑weekly sessions for multiple consecutive weeks (e.g., 4–12 weeks) in registries and observational studies.

PNS — definition

PNS definitionPercutaneous Peripheral Nerve Stimulation (PNS) places leads percutaneously or via implantation adjacent to peripheral nerves to deliver therapeutic impulses for postoperative or chronic neuropathic pain.

Device examplesExamples include StimRouter, SPRINT PNS, and other externally powered or implanted systems studied for TKA pain, chronic knee pain and CLBP with varying study designs.

Treatment course examplesRecent trials used percutaneous leads left in situ for defined courses (e.g., 60–90 days) with daily use targets (hours per day) during the treatment period.

PES/PEMF — definition

PES/PEMF definitionPulsed Electrical Stimulation (PES) and Pulsed Electromagnetic Field (PEMF) therapies are noninvasive modalities delivering time‑varying electrical fields or electromagnetic pulses intended to reduce pain or support tissue healing.

Clinical evidenceSystematic reviews report mixed short‑term benefits in osteoarthritis and CLBP but overall insufficient evidence to recommend routine use for chronic pain.

Protocol heterogeneityTreatment durations in trials vary (days to weeks), with subgroup analyses suggesting some function/pain benefits at particular durations (e.g., 4–6 weeks) but lacking long‑term follow‑up.

ReActiv8 restorative neurostimulation — definition/labeling

ReActiv8 labelReActiv8 is an implantable restorative neurostimulation system indicated for bilateral stimulation of the L2 medial branch for intractable chronic low back pain associated with multifidus dysfunction in adults who have failed conservative therapy.

Intended mechanismDevice stimulates multifidus to restore neuromuscular control and improve pain and disability in selected refractory mechanical CLBP populations.

Regulatory statusReActiv8 received premarket approval (PMA) and trials enrolled patients after >90 days of medical management and at least one course of physical therapy.

PEMF/PES (alternate)

PEMF/PES alternatePulsed electromagnetic field (PEMF) and pulsed electrical stimulation (PES) deliver noninvasive time‑varying fields to target tissue and have been studied in OA and CLBP with heterogeneous regimens.

Evidence limitationsMeta‑analyses highlight heterogeneity, small sample sizes and short follow‑up durations; long‑term effectiveness remains unproven.

Clinical implicationGiven limited and inconsistent evidence, PES/PEMF use for chronic pain is generally not supported as routine therapy in the policy excerpts.

ReActiv8 (alternate)

ReActiv8 alternate summaryRestorative neurostimulation (ReActiv8) is an implanted neuromuscular stimulator targeting multifidus dysfunction for refractory CLBP; trials report clinically meaningful improvements in subsets but overall evidence judged inconclusive due to study limitations.

Trial populationRandomized trial enrolled patients with refractory mechanical CLBP after >90 days of medical management and at least one attempt of physical therapy.

Safety signalsReported adverse events include pocket infections and explants; long‑term durability assessed in follow‑up cohorts with variable attrition.

Scrambler Therapy (ST) — definition

Scrambler Therapy (ST) definitionScrambler Therapy is a noninvasive transcutaneous neuromodulation approach (also called TEMPR/Calmare) delivering variable nonlinear waveforms via skin electrodes to provide non‑pain information to painful dermatomes for chronic pain relief.

Typical deliveryReported courses include daily 30–50 minute sessions over 10 working days with follow‑up ranging from days to months in trials.

Evidence stanceSystematic reviews find low‑quality and heterogeneous evidence; guidelines and HTAs generally find insufficient evidence to support routine use outside research for many indications.

Translingual Stimulation (TLS/TLNS/PoNS)

TLS / PoNS definitionTranslingual Stimulation (TLS/TLNS/PoNS) delivers electrical stimulation to the tongue via a mouthpiece device (PoNS) combined with physical therapy to improve balance and gait in neurologic conditions such as mmTBI and MS.

Adjunctive usePoNS/TLNS is intended as an adjunct to supervised targeted physical therapy programs rather than a standalone intervention.

Regulatory notePoNS received De Novo authorization (2021) for specified short‑term uses; pivotal trials combined device use with PT and reported high adherence and improvement in balance measures but with limitations in generalizability.

FES — definition

FES definitionFunctional Electrical Stimulation (FES) devices produce coordinated functional muscle contractions (e.g., to assist ambulation) using transcutaneous stimulation often with computer control and timing to support functional tasks.

Device reportingFES devices are reported under HCPCS (example E0770) and specific devices are identified in regulatory/device lists for coding purposes.

Clinical roleFES is used to produce functional movements (e.g., for spinal cord injury ambulation, drop foot) distinct from NMES used primarily for strengthening or re‑education.

NMES — alternate definition

NMES alternate definitionNMES is electrical stimulation applied to muscle to improve strength, motor control or swallowing function when nerve supply is intact; used across stroke, orthopedic rehab and ICU muscle preservation trials.

MechanismEvokes muscle contraction via transcutaneous currents to promote reinnervation, prevent disuse atrophy and augment voluntary control during rehabilitation.

Use casesExamples include prevention of quadriceps weakness after TKA, adjunctive gait training post‑stroke, and ICU muscle preservation protocols with heterogeneous dosing schedules.

PNS / PSFS / PNFS — alternate definition

PNS / PSFS / PNFS alternatePeripheral Nerve Stimulation (PNS) and Peripheral Subcutaneous Field Stimulation (PSFS/PNFS) deliver electrical stimulation to peripheral nerves or subcutaneous fields for pain relief; implantation may be percutaneous temporary leads or permanent implants.

Clinical trial examplesTrials include percutaneous 60‑day PNS for postoperative pain and implanted systems for chronic knee and back pain with varying reported responder rates and follow‑up durations.

Evidence limitationsEvidence derives from small RCTs, case series and observational cohorts; long‑term efficacy and ideal patient selection remain to be clarified.

MENS (alternate)

MENS (alternate)Microcurrent therapy delivers sub‑sensory microampere currents for pain and healing; small RCTs/meta‑analyses suggest modest short‑term pain reduction in selected conditions but evidence is limited.

Clinical caveatMENS differs mechanistically from TENS despite regulatory grouping; trial sizes are small and protocols short‑term, limiting conclusions about long‑term benefit.

Research needLarger, standardized RCTs are needed to establish efficacy and optimal protocols for MENS in specific indications.

PENS / PENFS (alternate)

PENS / PENFS (alternate)PENS uses percutaneous needle electrodes near target nerves; PENFS targets broader fields (often auricular) with low‑frequency currents — both are minimally invasive neuromodulation options studied for musculoskeletal, perioperative and pediatric DGBI conditions.

Protocol examplesExamples include once‑weekly PENS for three weeks (CTS trial) and weekly PENFS courses of 4–12 weeks in registry studies for pediatric functional GI disorders.

Evidence profileSystematic reviews report immediate to short‑term benefits for pain and postoperative outcomes, but heterogeneity and limited long‑term data constrain broad coverage recommendations.

TLNS / PoNS — definition

TLNS / PoNS definitionTranslingual neurostimulation (TLNS/PoNS) uses a mouthpiece to deliver electrical stimulation to the tongue combined with PT to promote neuroplasticity for motor deficits (balance/gait) in mmTBI and MS.

Regulatory/indication notePoNS received De Novo authorization for short‑term treatment adjunctive to supervised exercise in specified neurologic deficits; trials most often combined device use with targeted supervised PT.

Evidence caveatRCTs report improvements in balance and gait measures but both high‑ and low‑frequency arms frequently improved, limiting clear attribution to stimulation frequency alone.

Restorative neurostimulation / ReActiv8 (alternate)

Restorative neurostimulation (ReActiv8) alternateAn implanted restorative neurostimulation system intended to restore multifidus control in refractory mechanical CLBP; trials used scheduled stimulation post‑implant and reported responder rates but with methodological limitations.

Trial prerequisitesParticipants in pivotal trials had failed >90 days of medical management and at least one course of physical therapy before implant consideration.

Follow‑up and safetyLonger‑term follow‑up cohorts report sustained improvements in subsets but serious adverse events (including pocket infection and explant) were observed in a minority of participants.

Peripheral nerve stimulation (PNS) — background

PNS backgroundPeripheral nerve stimulation (PNS) encompasses implanted or percutaneous lead systems targeting peripheral nerves for chronic or postoperative pain management; clinical evidence includes randomized trials, case series and HTA reviews.

Device examplesDevices studied include StimRouter, SPRINT, and other systems; evidence summaries and HTAs highlight variable quality and need for larger controlled trials for many indications.

Clinical considerationsPercutaneous temporary PNS courses (e.g., 60 days) and permanent implants have different risk profiles and documentation/prior conservative therapy considerations in coverage decisions.

Neuromuscular electrical stimulation (NMES) — background

NMES backgroundNeuromuscular electrical stimulation (NMES) is used to elicit muscle contraction to improve strength, mobility or rehabilitation outcomes across orthopedic, neurologic and critical care settings when nerve supply is intact.

ApplicationsApplications include prevention of disuse atrophy, augmentation of strengthening after ACL/TKA, facilitation of gait or swallowing rehabilitation post‑stroke, and ICU muscle preservation protocols.

Evidence nuancesRCTs and systematic reviews show small‑to‑moderate short‑term benefits in many contexts but heterogeneity of protocols and study quality limit broad generalizations; NMES is typically an adjunct to standard rehab.

Electrical stimulation modalities — overview

Modalities listElectrical stimulation modalities reviewed include NMES, PNS, TENS, IFT/IFC, PES/PEMF, PENS/PENFS, restorative neurostimulation, scrambler therapy, translingual neurostimulation and FES among others.

Comparative evidenceNetwork and comparative analyses evaluated multiple modalities for conditions like knee OA and LBP, finding modality‑specific and sometimes short‑term advantages but overall heterogeneous evidence.

Policy implicationModalities differ by invasiveness, mechanism and evidence quality; coverage determinations require modality‑specific documentation and may require prior authorization for implantable or novel device therapies.